CompletedPhase 1

A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927

Lead sponsor

Vigil Neuroscience, Inc.

Asset

VG-3927

Listed sites

Recruiting sites

Enrollment

115

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥18

Primary endpoint

•Adverse Events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06343636

Org study IDVG3927-02.101

Timeline

Milestones

Study start2023-09-22actual

Study first posted2024-04-02actual

Primary completion2025-01-10actual

Study completion2025-01-10actual

Last update posted2025-02-07actual

Assets

Drug assets

VG-3927

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation

•The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent

Exclusion criteria

•The participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Adverse Events

Time frame:28 days post last dose

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.